CN116287211A - STRA6和miR-1249-5p在制备诊断子宫腺肌症的产品中的应用 - Google Patents
STRA6和miR-1249-5p在制备诊断子宫腺肌症的产品中的应用 Download PDFInfo
- Publication number
- CN116287211A CN116287211A CN202310297834.2A CN202310297834A CN116287211A CN 116287211 A CN116287211 A CN 116287211A CN 202310297834 A CN202310297834 A CN 202310297834A CN 116287211 A CN116287211 A CN 116287211A
- Authority
- CN
- China
- Prior art keywords
- mir
- stra6
- adenomyosis
- gene
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091057905 miR-1249 stem-loop Proteins 0.000 title claims abstract description 71
- 201000009274 endometriosis of uterus Diseases 0.000 title claims abstract description 68
- 208000005641 Adenomyosis Diseases 0.000 title claims abstract description 47
- 101000831949 Homo sapiens Receptor for retinol uptake STRA6 Proteins 0.000 title claims abstract description 38
- 102100024235 Receptor for retinol uptake STRA6 Human genes 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000014509 gene expression Effects 0.000 claims abstract description 48
- 101150092419 STRA6 gene Proteins 0.000 claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 108020004999 messenger RNA Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 10
- 229920002521 macromolecule Polymers 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 claims 1
- 201000007954 uterine fibroid Diseases 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 12
- 229940011871 estrogen Drugs 0.000 abstract description 10
- 239000000262 estrogen Substances 0.000 abstract description 10
- 238000003745 diagnosis Methods 0.000 abstract description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract description 5
- 229960001727 tretinoin Drugs 0.000 abstract description 5
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 108091036066 Three prime untranslated region Proteins 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 abstract description 2
- 230000004220 muscle function Effects 0.000 abstract description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 abstract description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 abstract description 2
- 108091070501 miRNA Proteins 0.000 description 29
- 239000002679 microRNA Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 16
- 238000001514 detection method Methods 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 210000000754 myometrium Anatomy 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108091086311 Oryctolagus cuniculus miR-1249 stem-loop Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108091044697 Homo sapiens miR-1249 stem-loop Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 208000016599 Uterine disease Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 238000009802 hysterectomy Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000002632 myometrial effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000011451 sequencing strategy Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100039561 ETS translocation variant 3-like protein Human genes 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 102000000794 Galectin 2 Human genes 0.000 description 1
- 108010001496 Galectin 2 Proteins 0.000 description 1
- 101000813733 Homo sapiens ETS translocation variant 3-like protein Proteins 0.000 description 1
- 101000969980 Homo sapiens Neurexin-2 Proteins 0.000 description 1
- 101000969975 Homo sapiens Neurexin-2-beta Proteins 0.000 description 1
- 101000591211 Homo sapiens Receptor-type tyrosine-protein phosphatase O Proteins 0.000 description 1
- 101000695838 Homo sapiens Receptor-type tyrosine-protein phosphatase U Proteins 0.000 description 1
- 101000704156 Homo sapiens Sarcalumenin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 238000012179 MicroRNA sequencing Methods 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 102100021345 Neurexin-2-beta Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108091085336 Oryctolagus cuniculus miR-152 stem-loop Proteins 0.000 description 1
- 108091085790 Oryctolagus cuniculus miR-29c stem-loop Proteins 0.000 description 1
- 108091085079 Oryctolagus cuniculus miR-328 stem-loop Proteins 0.000 description 1
- 108091085072 Oryctolagus cuniculus miR-365-1 stem-loop Proteins 0.000 description 1
- 108091086286 Oryctolagus cuniculus miR-660 stem-loop Proteins 0.000 description 1
- 108091086284 Oryctolagus cuniculus miR-671 stem-loop Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102100028516 Receptor-type tyrosine-protein phosphatase U Human genes 0.000 description 1
- 102100031881 Sarcalumenin Human genes 0.000 description 1
- 238000012167 Small RNA sequencing Methods 0.000 description 1
- 101000984202 Streptomyces rimosus Lipase Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- -1 WDR Proteins 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000009804 total hysterectomy Methods 0.000 description 1
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了一种STRA6和miR‑1249‑5p在制备诊断子宫腺肌症的产品中的应用,涉及生物技术领域。经发明人研究发现,子宫腺肌症患者血管平滑肌细胞膜上维A酸转运相关蛋白STRA6特异性高表达,而进一步研究发现STRA6的表达由miR‑1249‑5p介导,在雌激素作用下,miR‑1249‑5p可以直接靶向STRA6基因3'‑UTR调控细胞内维甲酸代谢影响血管平滑肌功能参与子宫腺肌症发生。因此,通过检测STRA6基因和miR‑1249‑5p的表达量能够实现子宫腺肌症的诊断。
Description
技术领域
本发明涉及生物技术领域,尤其是涉及一种STRA6和miR-1249-5p在制备诊断子宫腺肌症的产品中的应用。
背景技术
近年来,子宫腺肌症(adenomyosis,AM)的发生率明显上升,在30-50岁妇女中发生率为15-50%,在子宫内膜异位症不孕患者中发生率高达90%。腺肌症目前缺乏有效的治疗方法,诊断标准非常有限,常常诊断会延误,有的甚至长达10年之久。鉴此,阐明AM的发生机制对改善患者临床症状,提高妊娠率并挖掘有效的靶向治疗药物具有重要的理论意义和临床应用价值。
最近的研究结果表明MicroRNAs(miRs)在发育,信号传导,凋亡及细胞增殖发生等方面起到很重要的调节作用。研究已经证实组织中存在几百种的miRNAs,这些小分子RNAs性质稳定、含量丰富、易于定量检测,且存在显著的疾病特异性。现有成熟技术,包括定性和定量miRNA分子的技术表明利用miRNAs作为分子生物标志物的方法比传统的特异蛋白分子标记方法将更加有效,为生物标志物开拓了新视角。miRs在血管损伤,粥样硬化等血管性病变过程中通过调节其目标基因来调控血管的收缩和合成功能。Kuokkanen等证实人子宫内膜中雌激素参与了miRNA表达调控。
然而对于子宫腺肌症的检测上,仍存在以下缺点:
1、现有研究基于血清学miRNAs作为生物标志物进行诊断和监测AM发生,但是基于特定miRNAs及靶向蛋白用于子宫腺肌症检测、诊断和治疗相关药物潜在靶点的开发尚未见报道;
2、现有公开单一基因及其表达产物作为子宫疾病诊治的分子标志物。通过检测组织中该基因及其表达产物的含量可以判断受试者是否患有子宫疾病或者诊断受试者是否存在患有子宫相关疾病的风险。这种方法具有较为显著的局限性,细胞生理代谢调控精密,往往受到细胞内外环境因素等影响。
有鉴于此,特提出本发明。
发明内容
本发明的第一目的在于提供STRA6在制备诊断子宫腺肌症的产品中的应用。
本发明的第二目的在于提供miR-1249-5p在制备诊断子宫腺肌症的产品中的应用。
本发明的第三目的在于提供一种用于诊断子宫腺肌症的试剂,以解决上述问题中的至少一种。
本发明的第四目的在于提供STRA6的抑制剂在制备治疗子宫腺肌症的药物中的应用。
本发明的第五目的在于提供一种治疗子宫腺肌症的药物。
第一方面,本发明提供了STRA6在制备诊断子宫腺肌症的产品中的应用,所述STRA6为STRA6基因的mRNA或蛋白。
作为进一步技术方案,所述产品包括试剂或试剂盒,通过检测受试者体内STRA6基因的mRNA或蛋白的表达量来诊断子宫腺肌症。
第二方面,本发明提供了miR-1249-5p在制备诊断子宫腺肌症的产品中的应用,所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
作为进一步技术方案,所述产品包括试剂或试剂盒,通过检测受试者体内miR-1249-5p的表达量来诊断子宫腺肌症。
第三方面,本发明提供了一种用于诊断子宫腺肌症的试剂,所述试剂包括用于检测STRA6基因的mRNA的引物、用于检测STRA6基因的蛋白的生物大分子或用于检测miR-1249-5p的引物中的至少一种;
所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
作为进一步技术方案,所述生物大分子包括抗体或抗体功能片段。
第四方面,本发明提供了STRA6的抑制剂在制备治疗子宫腺肌症的药物中的应用,所述抑制剂抑制STRA6基因的表达。
作为进一步技术方案,所述抑制剂包括如下Ⅰ)-Ⅱ)中的至少一种:
Ⅰ)miR-1249-5p;
Ⅱ)含有miR-1249-5p的编码基因的重组载体;
所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
第五方面,本发明提供了一种治疗子宫腺肌症的药物,所述药物包括抑制STRA6基因表达的抑制剂。
作为进一步技术方案,所述抑制剂包括如下Ⅰ)-Ⅱ)中的至少一种:
Ⅰ)miR-1249-5p;
Ⅱ)含有miR-1249-5p的编码基因的重组载体;
所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
与现有技术相比,本发明具有如下有益效果:
经发明人研究发现,子宫腺肌症(AM)患者血管平滑肌细胞膜上维A酸(RetinoicAcid,RA)转运相关蛋白STRA6(stimulated by retinoic acid gene6homolog)特异性高表达,而进一步研究发现STRA6的表达由miR-1249-5p介导,在雌激素作用下,miR-1249-5p可以直接靶向STRA6基因3'-UTR调控细胞内维甲酸代谢影响血管平滑肌功能参与AM发生。因此,通过检测STRA6基因和miR-1249-5p的表达量能够实现子宫腺肌症的诊断。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为差异miRNA火山图;
图2为差异miRNA聚类热图;
图3为差异RNA火山图;
图4为差异mRNA差异表达基因通路示意图;
图5为250nM雌激素处理HA-VSMC差异miRNA与mRNA互相作用;
图6为荧光素酶报告基因实验检测miR-1249-5p与STRA6的靶向作用;
图7为STRA6在AM患者子宫内膜螺旋动脉血管平滑肌细胞中表达检测;
图8为小鼠实验子宫解剖图;
图9小鼠实验子宫组织HE染色图;
图10小鼠实验子宫免疫组化染色图。
具体实施方式
下面将结合实施方式和实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施方式和实施例仅用于说明本发明,而不应视为限制本发明的范围。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
第一方面,本发明提供了STRA6在制备诊断子宫腺肌症的产品中的应用,所述STRA6为STRA6基因的mRNA或蛋白。
经发明人研究发现,与健康受试者相比,STRA6基因的mRNA或蛋白在子宫腺肌症患者中差异表达上调,STRA6基因的mRNA或蛋白的表达量与子宫腺肌症相关,通过检测STRA6基因的mRNA或蛋白的表达量能够实现多囊卵巢综合征的诊断。
在一些优选的实施方式中,所述产品包括试剂或试剂盒,通过检测受试者体内STRA6基因的mRNA或蛋白的表达量来诊断子宫腺肌症。
第二方面,本发明提供了miR-1249-5p在制备诊断子宫腺肌症的产品中的应用,所述miR-1249-5p的核酸序列如SEQ ID NO.1所示:
GGGAGGAGGGAGGAGATGGGCCAAGTTCCCTCTGGCTGGAACG CCCTTCCCCCCCTTCTTCACCTG(SEQ ID NO.1)。
经发明人研究发现,STRA6的表达由miR-1249-5p介导,与健康受试者相比,miR-1249-5p在子宫腺肌症患者中差异表达下调,miR-1249-5p的表达量与子宫腺肌症相关,通过检测STRA6基因的mRNA或蛋白的表达量能够实现多囊卵巢综合征的诊断。
在一些优选的实施方式中,所述产品包括试剂或试剂盒,通过检测受试者体内miR-1249-5p的表达量来诊断子宫腺肌症。
第三方面,本发明提供了一种用于诊断子宫腺肌症的试剂,所述试剂包括用于检测STRA6基因的mRNA的引物、用于检测STRA6基因的蛋白的生物大分子或用于检测miR-1249-5p的引物中的至少一种;
所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
本发明提供的试剂通过特异性识别STRA6基因的mRNA的引物以实现对STRA6基因mRNA表达量的检测,通过特异性识别STRA6基因的蛋白的生物大分子以实现对STRA6基因蛋白表达量的检测,或者通过特异性识别miR-1249-5p的引物以实现对miR-1249-5p表达量的检测。本发明提供的试剂通过检测STRA6基因的mRNA的表达量、STRA6基因的蛋白的表达量或者miR-1249-5p的表达量来诊断子宫腺肌症。
在一些优选的实施方式中,miR-1249-5p的扩增引物如下:
hsa-mir-1249(40168-1)-P1:
TGTGGAAAGGACGCGGGATCCCAGGACTTTGGTGGATGTCGG(SEQ ID NO.2);
hsa-mir-1249(40168-1)-P2:
CAGCGGTTTAAACTTAAGCTAAAAAAGAGGCAAAAGGGATCCAC AG(SEQ ID NO.3)。
蛋白的检测剂可选用本领域技术人员所公知的试剂,例如能够与该蛋白发生抗原抗体反应,且标记有荧光标记的生物大分子等。
在一些优选的实施方式中,所述生物大分子包括抗体或抗体功能片段。
第四方面,本发明提供了STRA6的抑制剂在制备治疗子宫腺肌症的药物中的应用,所述抑制剂抑制STRA6基因的表达。
经发明人研究发现,抑制STRA6基因的表达有助于促进子宫腺肌症的治疗。
在一些优选的实施方式中,所述抑制剂包括如下Ⅰ)-Ⅱ)中的至少一种:
Ⅰ)miR-1249-5p;
Ⅱ)含有miR-1249-5p的编码基因的重组载体;
所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
经发明人研究发现,STRA6的表达由miR-1249-5p介导,miR-1249-5p为STRA6的抑制剂。
需要说明的是,本发明中,STRA6的抑制剂,可以包括miR-1249-5p、含有miR-1249-5p的编码基因的重组病毒或含有miR-1249-5p的编码基因的重组载体中的一种或两种或以上。
第五方面,本发明提供了一种治疗子宫腺肌症的药物,所述药物包括抑制STRA6基因表达的抑制剂。
经发明人研究发现,抑制STRA6基因的表达有助于促进子宫腺肌症的治疗,本发明提供的药物包括抑制STRA6基因表达的抑制剂,能够抑制STRA6基因的表达,因此能够用于子宫腺肌症的治疗。
在一些优选的实施方式中,所述抑制剂包括如下Ⅰ)-Ⅱ)中的至少一种:
Ⅰ)miR-1249-5p;
Ⅱ)含有miR-1249-5p的编码基因的重组载体;
所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
需要说明的是,本发明提供的治疗子宫腺肌症的药物,可以包括miR-1249-5p、含有miR-1249-5p的编码基因的重组病毒或含有miR-1249-5p的编码基因的重组载体中的一种或两种或以上。
下面通过具体的实施例和对比例进一步说明本发明,但是,应当理解为,这些实施例仅仅是用于更详细地说明之用,而不应理解为用于以任何形式限制本发明。
实施例1
材料与方法
一、资料来源
收集2019年10月-2020年11月期间于北京协和医院接受子宫切除手术治疗的患者的子宫组织,其中AM患者8名为研究组,对照组7名。AM患者纳入标准:①生育年龄女性,月经规律;②经全子宫切除手术及病理证实为子宫腺肌病患者;③术前3月内无激素治疗病史;④签署知情同意书。排除标准:①绝经后女性;②不能除外恶性疾病者;③同时合并其他激素相关性疾病。对照组的纳入标准:①已婚的生育年龄女性,月经规律;②无痛经、性交痛及慢性盆腔痛等症状;③育龄期CINIII及宫颈原位癌需行全子宫切除的患者;④术前3月内未应用激素类药物。排除标准:①绝经后女性;②术前有盆腔疼痛症状;③不能除外其他激素相关性疾病。
本研究入选患者均签署了知情同意书,实验流程获得北京协和医院学术与伦理学委员会批准。
二、研究方法
1.细胞培养:胸主动脉平滑肌细胞系(HA-VSMC)购自美国ATCC公司。将HA-VSMC接种在含体积分数10%胎牛血清、100mg/L链霉素、100kU/L青霉素的DNEM培养基中,分别设置0、250nmol/L雌激素处理组,其中0nmol/L雌激素为对照组,置于37℃、含体积分数5%CO2的细胞培养箱中孵育24小时后收集细胞进行相关实验。
2.子宫组织收集:所取组织用磷酸盐缓冲液洗去表面血污,将子宫螺旋动脉从子宫组织中分离出来,清除干净结缔组织和脂肪组织。于体积分数10%中性福尔马林固定液中固定4-6小时。常规梯度乙醇脱水、二甲苯透明、浸蜡、包埋。
3.免疫组织化学检测方法:将石蜡包埋的子宫组织做4μm厚度切片,常规脱蜡,并用体积分数3%过氧化氢15分钟封闭内源性过氧化物酶,体积分数10%山羊血清封闭30分钟,阻断非特异性染色。EDTA抗原修复液微波加热处理。滴加抗STRA6(Abcam,1:200)多克隆抗体,37℃孵育1小时。滴加辣根过氧化物酶标记的抗兔二抗,37℃孵育30分钟。滴加DAB工作液显微镜下显色。苏木素复染,氨水返蓝,梯度酒精脱水,中性树胶封片,显微镜下观察并拍照。由2位经验丰富的病理医师进行双盲阅片,每张切片上观察5个高倍视野(X200),分别对镜下阳性细胞的百分比和染色强度给予评分。
4.miRNA-seq建库:提取HA-VSMC细胞总RNA,Qubit精确定量浓度;Nanodrop检测OD260/280和OD260/230的比值分析RNA纯度;保证各组RNA样品浓度≥200ng/μL,总量≥2μg,OD260/280值在1.8~2.2之间,OD260/230≥2.0,且Agilent 2100Bioanalyzer检测的RIN≥7,以保证下游高质量small RNA-seq文库的构建。行3’和5’接头的连接;逆转录合成一链cDNA;PCR扩增、引入特异性标签;PAGE分离纯化miRNA文库;利用高分辨率的聚丙烯酰氨凝胶电泳(PAGE)来分离插入片段大小在22-24nt的miRNA文库:PAGE胶块切割回收文库产物。应用Qubit准确定量文库浓度,应用Agilent 2100Bioanalyzer确定文库片段大小分布,采用Illumina高通量测序平台,双端测序策略对文库进行测序。对原始测序序列进行过滤后用于后续分析。
5.mRNA-seq建库:取适量总RNA从中去除rRNA后纯化、片段化;逆转录合成一链cDNA;向合成一链cDNA的体系中加入二链合成预混体系3’末端加“A”反应;测序接头连接;文库片段筛选,PCR扩增cDNA文库后磁珠纯化。应用Qubit准确定量文库浓度,应用Agilent2100Bioanalyzer确定文库片段大小分布后上机测序。采用Illumina高通量测序平台,2×150bp双端测序策略对文库进行测序。测序得到的原始测序序列,里面含有一些带接头的、低质量的reads,为了保证信息分析质量,使用TrimGalore方法(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)对raw reads进行过滤,得到clean reads用于后续分析。
6.共转染:使用共转染试剂lipo3000将miR-1249-5p过表达质粒或miR-1249-5p空载质粒、靶基因野生型(STRA6野生型)或突变型(STRA6突变型)以及海肾素荧光载体转染至293T细胞中,24-28后在荧光显微镜下观察转染效率。
接种细胞:取对数生长期细胞(生长状态良好)均匀接种于24孔板中,孔板置于细胞培养箱(37℃、5%的CO2)中培养24h,使转染时细胞贴壁良好且密度达50%左右;
稀释Lipo3000:每孔用25ul Opti稀释1.5ul Lipo3000,充分混匀。
稀释质粒:每孔用25ul Opti-MEM稀释质粒(miR-1249-5p过表达质粒或miR-1249-5p空载质粒1ug、靶基因野生型或突变型0.2ug、海肾素荧光载体0.04ug),再加2ulLipo3000。
制备混合液:将稀释的质粒加入到稀释的Lipo3000中,轻轻吹打混匀,室温孵育15min。
将24孔板中的液体吸出,用PBS清洗2次,吸净24孔板中液体,加入无双抗无血清培养基。
将转染复合物依次加入预先接种好细胞的24孔板中,每孔最终反应体系500ul,轻轻混匀;6-8小时换液,换成含双抗和血清的完全培养基。
将24孔板置于细胞培养箱(37℃、5%的CO2)中培养。
7.Luciferase检测
配制Dual-Stop&/>检测试剂D:实验前,计算所需的Dual-/>Stop&检测试剂的量。用Dual-/>Stop&/>缓冲液以1:100将Dual-/>Stop&/>底物稀释至一个新的容器中。
将培养有细胞的24孔从培养箱中取出,放置几分钟使培养板平衡至室温。
检测萤火虫萤光素酶活性:用移液器向各孔中加入与培养基等体积的C检测试剂(对于24孔板向生长在300μl培养基的细胞中加入300μl C检测试剂),混合均匀。待细胞充分裂解后,将所有样品转移至不透光的96孔白板中检测。
检测海肾萤光素酶活性:向各孔中加入与初始培养基体积相同的D检测试剂75μl,D检测试剂需在加入C检测试剂之后4小时以内加入。等待至少10分钟后检测海肾萤光素酶信号。
计算各孔主报告基因与内参报告基因信号的比值。使用对照组的比值将各实验组的比值进行归一化。
三、统计学方法
结果
一、miRNA-seq差异表达分析
1.根据已知的和新预测的miRNA的表达水平,利用R软件包DESeq2筛选出差异表达的miRNA,P<0.05且log2(fold change)≠0被定义为两组之间的差异表达miRNA,其中log2(fold change)>0标记为上调miRNA(Up);log2(fold change)<0标记为下调miRNA(Down),具有显著差异的miRNA数目统计如下表所示。见表1。
表1显著差异的miRNA数目在HA-VSMC各组间的统计
250nM雌激素处理组较对照组比较,共有56个miRNA发生显著性变化,其中上调32个,下调24个;上调包括ocu-miR-660-3p,ocu-miR-328-3p,ocu-miR-29c-3p等;下调包括ocu-miR-1249-5p,ocu-miR-671-5p,ocu-miR-365-5p,ocu-miR-152-5p等。结果如图1何图2所示。其中图1为差异miRNA火山图,红色点表示处理组相对于对照样本control表达量上调的miRNA,绿色点表示下调miRNA;图2为差异miRNA聚类热图,红色表示基因在样品中高表达,绿色表示基因在样品低表达。
二、mRNA-seq差异表达分析
采用Deseq2软件分析差case组(处理组)与control组(对照组)的差异表达基因。Type为筛选结果,满足P<0.05且|log2(fold change)|>1的为差异基因,其中log2(foldchange)>1标记为上调基因(Up);log2(fold change)<-1标记为下调基因(Down),显著差异基因数目见表2。
表2.显著差异基因数目统计表
250nM雌激素处理组较对照组比较,共有89个mRNA发生显著性变化,其中上调47个,下调42个;上调包括LGALS2、ETV3L、WDR17、STRA6等;下调包括NRXN2、SRL、PTPRO等。结果如图3和图4所示。其中图3为差异RNA火山图,红色点表示处理组相对于对照样本control表达量上调的mRNA,绿色点表示下调mRNA;图4为差异mRNA差异表达基因通路示意图,红色表示处理组相对于对照样本control差异显著基因,纵坐标表示差异基因所在通路。
三、差异miRNA与差异RNA调控互作预测
ocu-miR-1249-5p随着雌激素浓度的增加该miRNA的表达量越低,其靶向基因STRA6 mRNA表达量随着浓度的增加而增加。软件预测miR-1249-5p与STRA6结合位置及结合力大小的结果如图5所示,表明miR-1249-5p与STRA6理论存在靶向调控关系。
四、miR-1249-5p与STRA6存在靶向作用
采用双荧光素酶报告基因实验检测miR-1249-5p与STRA6 3'-UTR靶向关系。结果显示,靶基因野生型对照组和靶基因野生型miR-1249-5p质粒组的标准化荧光强度比较,差异具有统计学意义(P<0.05),靶基因突变型对照组和靶基因突变型miR-1249-5p质粒组的标准化荧光强度比较,差异不具有统计学意义(P>0.05),即miR-1249-5p与STRA6存在靶向作用。结果如图6所示。
五、ocu-miR-1249-5p靶向STRA6基因在AM患者子宫内膜动脉的表达情况
免疫组织化学染色显示,与对照组(Control)相比,AM患者子宫内膜螺旋动脉血管平滑肌细胞中STRA6的表达明显增加,具有统计学差异(P<0.05),结果如图7所示。
六、腺肌症动物模型构建
怀孕的ICR小鼠(孕龄约15-16天)分娩后,每只母鼠及其幼鼠关在同一个笼子里。从出生后第1天到第4天(PNDs),通过口服管饲法,每天给予雌性新生儿1μg/g体重的他莫昔芬(TAM),混悬于花生油/卵磷脂/炼乳混合物(2:0.2:3v/v/v)或相同体积的溶剂中。出生后第5-7周,向小鼠的两个子宫角连续注射10μl SiRNA1,记为adenomyosis+stra6 siRNA1组(siRNA1干扰腺肌症模型组),向小鼠的两个子宫角连续注射10μl SiRNA2,记为adenomyosis+stra6 siRNA2组(siRNA2干扰腺肌症模型组)。每周2次,持续3周。观察STRA6干扰能否改善腺肌症发生。所有小鼠在出生后第8周处死,结果发现siRNA干扰组子宫增厚情况明显改善。相较于对照组小鼠子宫,子宫腺肌病小鼠的子宫腔增大,黏膜层相对增厚,内环和外纵平滑肌肌层均变薄肌层内可见子宫腺。小RNA干扰组处理后,子宫腔有缩小,肌层完整性增加,肌间腺体数量减少,表明通过小RNA抑制STRA6,对于子宫腺肌症具有一定的治疗作用。结果如图8,9,10所示。图8为小鼠实验子宫解剖图,从左至右分别为对照组,腺肌症模型组,siRNA1干扰腺肌症模型组和siRNA2干扰腺肌症模型组(蓝色箭头指向子宫组织)。
图9为小鼠实验子宫组织HE染色图,分别取自对照组,腺肌症模型组,siRNA1干扰腺肌症模型组和siRNA2干扰腺肌症模型组。EM代表子宫内膜,MM代表子宫肌层。分别观察肌间子宫腺体的数量及子宫腺体浸润肌层的深度。
图10为小鼠实验子宫免疫组化染色图,分别取自对照组,腺肌症模型组,siRNA1干扰腺肌症模型组和siRNA2干扰腺肌症模型组。用CK8,α-SMA和E-cadherin作为抗体杂交,分别观察各蛋白阳性富集面积与体积大小。
SiRNA1的序列为:UAGGUUGCUGAAGAGGACC(dT)(dT)(SEQ ID NO.4);
SiRNA2的序列为:UUGUACUGGAUACCAAAGG(dT)(dT)(SEQ ID NO.5)。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (10)
1.STRA6在制备诊断子宫腺肌症的产品中的应用,其特征在于,所述STRA6为STRA6基因的mRNA或蛋白。
2.根据权利要求1所述的应用,其特征在于,所述产品包括试剂或试剂盒,通过检测受试者体内STRA6基因的mRNA或蛋白的表达量来诊断子宫腺肌症。
3.miR-1249-5p在制备诊断子宫腺肌症的产品中的应用,其特征在于,所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
4.根据权利要求3所述的应用,其特征在于,所述产品包括试剂或试剂盒,通过检测受试者体内miR-1249-5p的表达量来诊断子宫腺肌症。
5.一种用于诊断子宫腺肌症的试剂,其特征在于,所述试剂包括用于检测STRA6基因的mRNA的引物、用于检测STRA6基因的蛋白的生物大分子或用于检测miR-1249-5p的引物中的至少一种;
所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
6.根据权利要求5所述的试剂,其特征在于,所述生物大分子包括抗体或抗体功能片段。
7.STRA6的抑制剂在制备治疗子宫腺肌症的药物中的应用,其特征在于,所述抑制剂抑制STRA6基因的表达。
8.根据权利要求7所述的应用,其特征在于,所述抑制剂包括如下Ⅰ)-Ⅱ)中的至少一种:
Ⅰ)miR-1249-5p;
Ⅱ)含有miR-1249-5p的编码基因的重组载体;
所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
9.一种治疗子宫腺肌症的药物,其特征在于,所述药物包括抑制STRA6基因表达的抑制剂。
10.根据权利要求9所述的药物,其特征在于,所述抑制剂包括如下Ⅰ)-Ⅱ)中的至少一种:
Ⅰ)miR-1249-5p;
Ⅱ)含有miR-1249-5p的编码基因的重组载体;
所述miR-1249-5p的核酸序列如SEQ ID NO.1所示。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310297834.2A CN116287211A (zh) | 2023-03-24 | 2023-03-24 | STRA6和miR-1249-5p在制备诊断子宫腺肌症的产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310297834.2A CN116287211A (zh) | 2023-03-24 | 2023-03-24 | STRA6和miR-1249-5p在制备诊断子宫腺肌症的产品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116287211A true CN116287211A (zh) | 2023-06-23 |
Family
ID=86779582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310297834.2A Pending CN116287211A (zh) | 2023-03-24 | 2023-03-24 | STRA6和miR-1249-5p在制备诊断子宫腺肌症的产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116287211A (zh) |
-
2023
- 2023-03-24 CN CN202310297834.2A patent/CN116287211A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tingö et al. | Non-coding RNAs in human breast milk: A systematic review | |
Naji et al. | Expression of miR-15a, miR-145, and miR-182 in granulosa-lutein cells, follicular fluid, and serum of women with polycystic ovary syndrome (PCOS) | |
JP2019531741A (ja) | 胃癌の生物学的特性に基づく群区分および予後予測システム | |
Li et al. | MicroRNA-451 plays a role in murine embryo implantation through targeting Ankrd46, as implicated by a microarray-based analysis | |
CN110016504B (zh) | CDR1as在神经管畸形产前筛查中的应用、神经管畸形产前筛查的产品和方法 | |
CN114854851B (zh) | 一种血浆来源的外泌体lncRNA在制备药物性肝损伤生物标志物中的应用 | |
Gad et al. | Plasma extracellular vesicle miRNAs as potential biomarkers of superstimulatory response in cattle | |
Xie et al. | MiR-423-5p may regulate ovarian response to ovulation induction via CSF1 | |
US10088482B2 (en) | Prognosis of oesophageal and gastro-oesophageal junctional cancer | |
CN108796065B (zh) | Fam127a在妊娠疾病中的应用 | |
Bae et al. | Identification and analysis of novel endometriosis biomarkers via integrative bioinformatics | |
CN109371124A (zh) | miR-6802-3p在绝经后妇女骨质疏松症早期诊断中的应用 | |
CN110029166B (zh) | 长链非编码rna linc00205在制备诊断卵巢癌试剂或治疗卵巢癌药物中的应用 | |
CN109988829B (zh) | 一种检测神经管畸形的分子标志物及其应用 | |
Cheval et al. | Plasticity of mouse renal collecting duct in response to potassium depletion | |
CN116287211A (zh) | STRA6和miR-1249-5p在制备诊断子宫腺肌症的产品中的应用 | |
Shen et al. | METTL3 and METTL14-mediated N6-methyladenosine modification promotes cell proliferation and invasion in a model of endometriosis | |
Chen et al. | Exosomes—a potential indicator and mediator of cleft lip and palate: a narrative review | |
CN107779503A (zh) | 阿尔茨海默相关的差异表达基因及其应用 | |
CN108165627B (zh) | 一种诊治盆腔脱垂的分子标志物 | |
US20220268780A1 (en) | Methods of predicting endometrial receptivity | |
EP3036345A2 (en) | Method and composition for detection of oncogenic hpv | |
CN111172161B (zh) | 一种长非编码rna及其在诊断/治疗子痫前期中的应用 | |
Chen et al. | Functional characterization of DLK1/MEG3 locus on chromosome 14q32. 2 reveals the differentiation of pituitary neuroendocrine tumors | |
CN111471682A (zh) | miR-23a作为诊断和治疗胃癌伪管生成标志物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |